Perspective Therapeutics (NYSEAMERICAN:CATX) Given New $13.00 Price Target at HC Wainwright

Key Points

• HC Wainwright raised its price target on Perspective Therapeutics from $12.00 to $13.00 and maintained a "buy" rating, a target that the report says implies about a 192.13% upside from the company's current price.
• Analyst consensus is broadly positive—one analyst lists a Strong Buy and eight list Buy, with an average price target of $12.63 and individual targets from other firms ranging roughly $11 to $16.
• Perspective Therapeutics is trading around $4.45 (12‑month range $1.60–$6.16) but reported a loss (‑$0.51 EPS last quarter) and minimal revenue, while showing strong liquidity (current and quick ratios of 5.17), very low debt (debt/equity 0.01), and about 54.7% institutional ownership.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) had its price target raised by stock analysts at HC Wainwright from $12.00 to $13.00 in a report issued on Monday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price objective would indicate a potential upside of 192.13% from the company's current price.

A number of other brokerages have also weighed in on CATX. Wedbush reiterated an "outperform" rating and issued a $11.00 price target on shares of Perspective Therapeutics in a report on Wednesday, March 18th. B. Riley Financial increased their target price on Perspective Therapeutics from $11.00 to $13.00 and gave the stock a "buy" rating in a research report on Wednesday, March 18th. BTIG Research reiterated a "buy" rating and issued a $14.00 target price on shares of Perspective Therapeutics in a report on Tuesday, March 17th. Royal Bank Of Canada lowered their price target on Perspective Therapeutics from $18.00 to $14.00 and set an "outperform" rating for the company in a research report on Tuesday, March 17th. Finally, Piper Sandler initiated coverage on Perspective Therapeutics in a report on Thursday, February 19th. They issued an "overweight" rating and a $16.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $12.63.

Perspective Therapeutics Stock Performance

CATX opened at $4.45 on Monday. Perspective Therapeutics has a 12 month low of $1.60 and a 12 month high of $6.16. The business has a 50-day moving average of $4.37 and a two-hundred day moving average of $3.44. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.17 and a current ratio of 5.17.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last released its earnings results on Monday, March 16th. The company reported ($0.51) earnings per share (EPS) for the quarter. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%.The company had revenue of $0.04 million during the quarter. Sell-side analysts anticipate that Perspective Therapeutics will post -0.88 EPS for the current fiscal year.

Institutional Trading of Perspective Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. increased its holdings in Perspective Therapeutics by 184.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company's stock valued at $29,000 after purchasing an additional 5,475 shares in the last quarter. Aigen Investment Management LP acquired a new position in shares of Perspective Therapeutics during the fourth quarter worth about $28,000. nVerses Capital LLC purchased a new stake in shares of Perspective Therapeutics in the fourth quarter worth about $31,000. Engineers Gate Manager LP acquired a new stake in shares of Perspective Therapeutics in the fourth quarter valued at about $35,000. Finally, AXQ Capital LP grew its stake in shares of Perspective Therapeutics by 24.2% in the fourth quarter. AXQ Capital LP now owns 12,749 shares of the company's stock valued at $35,000 after buying an additional 2,481 shares in the last quarter. 54.66% of the stock is owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.